Leuprolide acetate is used for: Uterine fibroids; Endometriosis; Prostate cancer.
Recorded in the NepalDoc medicine catalog for Leuprolide acetate.
LUPRON DEPOT 3.75 mg is a gonadotropin-releasing hormone (GnRH) agonist indicated for: Endometriosis Management of endometriosis, including pain relief and reduction of endometriotic lesions. In combination with a norethindrone acetate for initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms.
From the U.S. FDA-approved label for Leuprolide acetate. Full label: DailyMed.
LUPRON DEPOT 3.75 mg is a gonadotropin-releasing hormone (GnRH) agonist indicated for: Endometriosis Management of endometriosis, including pain relief and reduction of endometriotic lesions. In combination with a norethindrone acetate for initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms.
From the U.S. FDA-approved label for Leuprolide acetate. Full label: DailyMed.
LUPRON DEPOT 3.75 mg for 1-month administration, given by a healthcare provider as a single intramuscular injection. LUPRON DEPOT 3.75 mg has different release characteristics than LUPRON 11.25 mg and is dosed differently. Do not substitute LUPRON DEPOT 3.75 mg for LUPRON DEPOT 11.25 mg.
Directions from the U.S. FDA-approved label for Leuprolide acetate — your doctor or pharmacist may advise differently.
LUPRON DEPOT 3.75 mg is contraindicated in women with the following: Hypersensitivity to gonadotropin-releasing hormone (GnRH), GnRH agonist analogs, including leuprolide acetate, or any of the excipients in LUPRON DEPOT 3.75 mg Undiagnosed abnormal uterine bleeding Pregnancy When norethindrone acetate is administered with LUPRON DEPOT 3.75 mg, the contraindications to the use of norethindrone acetate also apply to this combination regimen.
Excerpt from the U.S. FDA-approved label for Leuprolide acetate. Talk to a pharmacist or doctor before use.
Loss of bone mineral density (BMD): Duration of treatment is limited by risk of bone mineral density. When using for management of endometriosis: combination use with norethindrone acetate is effective in reducing loss of BMD; do not retreat without combination norethindrone acetate. Assess BMD before retreatment. Embryo-Fetal Toxicity: May cause fetal harm. Exclude pregnancy before initiating treatment if clinically indicated and discontinue use if pregnancy occurs. Use non-hormonal methods of contraception only.
Warnings and precautions excerpt from the U.S. FDA-approved label for Leuprolide acetate — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are described elsewhere in the labeling: Loss of Bone Mineral Density Severe Cutaneous Adverse Reactions Hypersensitivity Reactions Initial Flare of Symptoms with Management of Endometriosis Convulsions Clinical Depression Most common adverse reactions (>10%) in clinical trials were hot flashes/sweats, headache/migraine, vaginitis, depression/emotional lability, general…
Excerpt from the U.S. FDA-approved label for Leuprolide acetate — not a complete list. Talk to a pharmacist or doctor about side effects.
5 brands · 4 makers in the NepalDoc catalog — see the full Leuprolide acetate guide →
Store between 20° to 25°C (68° to 77°F).
Storage information from the U.S. FDA-approved label for Leuprolide acetate.
What is Lulizol?
Lulizol 1%w/w Cream is a Leuprolide acetate medicine made by klm laboratories Pvt Ltd. It comes as 1%w/w Cream.
What is Lulizol used for?
Leuprolide acetate is used for Uterine fibroids, Endometriosis, Prostate cancer.
What is the generic name of Lulizol?
The generic name of Lulizol is Leuprolide acetate.
Which brands of Leuprolide acetate are available in Nepal?
5 brands of Leuprolide acetate are listed in the NepalDoc catalog, from 4 makers — including Luprid Depot 3.75mg Injection, Lupride 3.75mg Injection, Luprodex 3.75mg Injection, Luprorin 3.75mg Injection.
What are the side effects of Leuprolide acetate?
The following clinically significant adverse reactions are described elsewhere in the labeling: Loss of Bone Mineral Density Severe Cutaneous Adverse Reactions Hypersensitivity Reactions Initial Flare of Symptoms with Management of Endometriosis Convulsions Clinical Depression Most common adverse reactions (>10%) in clinical trials were hot flashes/sweats, headache/migraine, vaginitis, depression/emotional lability, general…
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
